IE
NAMS icon

Israel Englander’s NewAmsterdam Pharma NAMS Stock Holding History

Israel Englander’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17M Buy
501,614
+197,766
+65% +$6.52M 0.01% 1768
2026
Q1 		$9.73M Buy
303,848
+49,252
+19% +$1.6M ﹤0.01% 2194
2025
Q4 		$8.93M Buy
+254,596
New +$9.27M ﹤0.01% 2382
2025
Q3 		– Sell
-27,345
Closed -$495K – 6308
2025
Q2 		$495K Buy
27,345
+13,045
+91% +$238K ﹤0.01% 4919
2025
Q1 		$293K Sell
14,300
-479,930
-97% -$10.7M ﹤0.01% 5112
2024
Q4 		$12.7M Buy
494,230
+477,481
+2,851% +$10.1M 0.01% 1952
2024
Q3 		$278K Sell
16,749
-1,148,680
-99% -$19.9M ﹤0.01% 5246
2024
Q2 		$22.4M Buy
1,165,429
+217,902
+23% +$4.37M 0.01% 1396
2024
Q1 		$22.4M Sell
947,527
-378,576
-29% -$7.68M 0.01% 1471
2023
Q4 		$14.8M Buy
1,326,103
+281,319
+27% +$2.58M 0.01% 1819
2023
Q3 		$9.66M Buy
1,044,784
+671,232
+180% +$7.27M ﹤0.01% 2084
2023
Q2 		$4.44M Buy
373,552
+317,919
+571% +$4.22M ﹤0.01% 2775
2023
Q1 		$748K Buy
+55,633
New +$702K ﹤0.01% 4331

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Israel Englander's NAMS Position: Q2 2026 in Review

Israel Englander increased its NewAmsterdam Pharma (NAMS) stake by 65% in Q2 2026, buying an estimated $6.52M and bringing the position to 501,614 shares worth $17M. The position accounts for 0.01% of the portfolio, ranked #1768.

Israel Englander first reported a position in NAMS in Q1 2023 and has held it in 13 quarters since. The position peaked at $22.4M in Q1 2024. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Israel Englander held 501,614 shares of NewAmsterdam Pharma worth $17M as of Q2 2026.
  • Israel Englander bought 197,766 NewAmsterdam Pharma shares in Q2 2026, an estimated $6.52M.
  • NewAmsterdam Pharma made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1768 holding.
  • Israel Englander first reported a position in NewAmsterdam Pharma in Q1 2023 and has held it in 13 quarters since.
  • Israel Englander's NewAmsterdam Pharma position peaked at $22.4M in Q1 2024.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.